Test Price
2,800 AED✅ Home Collection Available
ALPL Gene Hypophosphatasia (Infantile) NGS Test in UAE | 2800 AED | DHA Licensed
Executive Summary and Core Metrics
Definitive Molecular Diagnosis for Infantile Hypophosphatasia
Diagnose infantile hypophosphatasia with definitive molecular precision. This Next‑Generation Sequencing (NGS) test achieves 99.9% analytical sensitivity for mutations in the ALPL gene, replacing the diagnostic uncertainty of biochemical enzyme assays. Our ISO‑accredited laboratory ensures rapid, secure processing with comprehensive genetic counselling support.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited Next‑Generation Sequencing (NGS).
- Premium Logistics: VIP Mobile Phlebotomy and Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic post‑test clinical interpretation by a DHA‑licensed genetics specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview and Methodology
Infantile hypophosphatasia is a severe metabolic bone disorder caused by inactivating mutations in the ALPL gene, which encodes tissue‑nonspecific alkaline phosphatase (TNSALP). This Next‑Generation Sequencing assay examines the entire coding region and intron‑exon boundaries of the ALPL gene, detecting single nucleotide variants, small insertions or deletions, and copy number variations with high clinical confidence.
| Feature | Our ALPL NGS Test | Alkaline Phosphatase (ALP) Enzyme Assay |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) — full gene analysis | Colorimetric biochemical assay |
| Diagnostic Sensitivity | 99.9% | Variable; may miss subtle mutations |
| Turnaround Time | 3–4 Weeks | 1–3 Days |
| Result Type | Definitive genetic mutation report (ACMG‑classified) | Suspicion only; requires genetic confirmation |
Physician Insight and Safety Protocols
“Next‑generation sequencing of the ALPL gene represents a significant diagnostic leap, offering a definitive answer where biochemical assays only hint. A negative result effectively rules out infantile hypophosphatasia, while a positive result guides targeted therapy. However, the data must always be interpreted within the full clinical context by a qualified geneticist.”
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory and Safety Considerations
Medication and Treatment Warning
Do not alter or discontinue any prescribed medications or therapies based solely on preliminary discussions or online research. Treatment plans must only be modified by your supervising physician. If your child experiences respiratory distress, seizures, or sudden failure to thrive, seek emergency care immediately.
Exclusion Criteria and Emergency Red Flags
- Exclusion: This test is not suitable for individuals who have received an allogeneic bone marrow transplant due to potential donor DNA interference. A mandatory pre‑test genetic counselling session with pedigree charting is required before sample collection.
- Seek emergency care if: Respiratory distress, seizures, or sudden failure to thrive — do not wait for test results.
- Pre‑Test Requirement: Clinical history and a genetic counselling session with pedigree charting are mandatory before sample collection.
Patient FAQ and Clinical Guidance
1. What is the ALPL gene NGS test for infantile hypophosphatasia?
It is a next‑generation sequencing analysis that detects mutations in the ALPL gene to confirm infantile hypophosphatasia diagnosis with 99.9% sensitivity. This test reads the entire genetic code of the ALPL gene, identifying single‑nucleotide variants, small deletions, and copy‑number changes that cause the disease. It is the gold standard when clinical signs and low alkaline phosphatase suggest the infantile form.
2. How does this NGS test compare to standard alkaline phosphatase (ALP) assays?
With 99.9% analytical sensitivity and specificity, this NGS test virtually eliminates false‑negative results seen in biochemical assays. Our ISO 9001:2015‑certified laboratory uses validated bioinformatics pipelines. The report includes variant classification per ACMG guidelines, offering clinicians a certainty level that biochemical tests cannot match.
3. What is the cost of the test and does insurance cover it in the UAE?
The test is priced at 2,800 AED, inclusive of home collection and genetic counselling, with direct insurance verification via WhatsApp +971 54 548 8731. Many UAE insurance plans cover medically necessary genetic testing for paediatric metabolic disorders. Our billing team checks your policy instantly, and we assist with pre‑authorization. For self‑pay patients, all‑inclusive pricing guarantees no hidden fees.
4. How should I prepare my child for the sample collection?
No special preparation such as fasting is required for this genetic test. Our trained phlebotomist will collect a peripheral whole blood sample from your child in the comfort of your home. The sample is transported via a temperature‑controlled cold chain to our ISO‑accredited laboratory in Dubai Healthcare City.
5. When will I receive the results and how are they delivered?
The turnaround time for this comprehensive NGS test is 3 to 4 weeks. Results are delivered electronically via a secure, encrypted patient portal and are reviewed with you during a telephonic consultation with our DHA‑licensed genetics specialist, ensuring you fully understand the findings and their implications.
UAE Regulatory and Data Privacy Adherence
Your genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and handled in strict compliance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical safety procedures and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
DNA Labs UAE operates under DHA Facility License Number 1143, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. We are committed to maintaining the highest standards of data security, diagnostic accuracy, and patient confidentiality.
Clinical and Logistical Metadata
| Test Name | ALPL Gene Hypophosphatasia (Infantile) NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | E83.30 |
| LOINC Code | 82163-2 |
| DHA Facility License & Laboratory Address | 1143 / Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians